PAVmed Inc. Research And Development Expense

• PAVmed Inc. showed a decrease of -24.3% in Research And Development Expense from 2024 to 2025.
• This data is from PAVmed Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2015: $16.0 thousand | Q2 2015: $67.5 thousand | Q3 2015: $264.5 thousand | Q4 2015: $141.3 thousand | Q1 2016: $179.1 thousand | Q2 2016: $355.0 thousand | Q3 2016: $578.5 thousand | Q4 2016: $607.0 thousand | Q1 2017: $656.7 thousand | Q2 2017: $701.7 thousand | Q3 2017: $704.9 thousand | Q1 2018: $563.2 thousand | Q2 2018: $1.15 million | Q3 2018: $1.17 million | Q1 2019: $1.45 million | Q2 2019: $1.41 million | Q3 2019: $1.52 million | Q1 2020: $2.63 million | Q2 2020: $2.13 million | Q3 2020: $2.62 million | Q1 2021: $3.32 million | Q2 2021: $4.26 million | Q3 2021: $5.31 million | Q1 2022: $5.93 million | Q2 2022: $6.74 million | Q3 2022: $6.20 million | Q1 2023: $4.05 million | Q2 2023: $3.47 million | Q3 2023: $3.16 million | Q1 2024: $1.94 million | Q2 2024: $1.64 million | Q3 2024: $1.54 million | Q1 2025: $787.0 thousand | Q2 2025: $790.0 thousand | Q3 2025: $1.09 million.
• Over the full 11 years of available data (2015 to 2025), PAVmed Inc.'s Research And Development Expense has grown by 818.0%.
• Historical annual values: Fiscal year 2025: $4.49 million | Fiscal year 2024: $5.93 million | Fiscal year 2023: $14.28 million | Fiscal year 2022: $25.34 million | Fiscal year 2021: $19.85 million | Fiscal year 2020: $10.96 million | Fiscal year 2019: $6.63 million | Fiscal year 2018: $4.25 million | Fiscal year 2017: $2.62 million | Fiscal year 2016: $1.72 million | Fiscal year 2015: $489.3 thousand.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026